Confronto
Maridebart Cafraglutide vs. Semaglutid
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
nessun dato
910463-68-2
Peso molecolare
nessun dato
4113.6 g/mol
Emivita
nessun dato
165 h
Sequenza
nessun dato
modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerMeccanismo d'azione
Maridebart Cafraglutide
MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
1
4
di cui sull'uomo
1
3
Effetti registrati
2
3
Contraddizioni aperte
0
1
Eventi avversi documentati
1
5
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Maridebart Cafraglutide and Semaglutid?
- Maridebart Cafraglutide is classified as "Metabolico", while Semaglutid is classified as "Metabolico". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Maridebart Cafraglutide or Semaglutid?
- The highest available evidence level is "RCT sull'uomo" for Maridebart Cafraglutide and "RCT sull'uomo" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Maridebart Cafraglutide and Semaglutid in Germany and the United States?
- Germania: Maridebart Cafraglutide — Non approvato, Semaglutid — Su prescrizione. Stati Uniti: Maridebart Cafraglutide — Non approvato, Semaglutid — Su prescrizione. These are factual summaries with source and review date on the individual pages.